Response to Sarbey: Why Standard Drug Treatments for the “Death Rattle” Should Be Discontinued (DOI: 10.1089/jpm.2021.0568): Death Rattle in Dying Patients
Restricted accessLetterFirst published online May, 2022
Response to Sarbey: Why Standard Drug Treatments for the “Death Rattle” Should Be Discontinued (DOI: 10.1089/jpm.2021.0568): Death Rattle in Dying Patients
SarbeyB: Why standard drug treatments for the “death rattle” should be discontinued. J Palliat Med, 2022; 25:180.
2.
MercadanteS: Death rattle: Critical review and research agenda. Support Care Cancer, 2014; 22:571–575.
3.
MercadanteS, MarinangeliF, MaseduF, et al.: Hyoscine butylbromide for the management of death rattle: Sooner rather than later. J Pain Symptom Manage, 2018; 56:902–907.
4.
van EschHJ, van ZuylenL, GeijtemanECT, et al.: Effect of prophylactic subcutaneous scopolamine butylbromide on death rattle in patients at the end of life: The SILENCE Randomized Clinical Trial. JAMA, 2021; 326:1268–1276.
5.
CampbellML: Assuaging listener distress from patient death rattle. Ann Palliat Med, 2019; 8(Suppl 1):S58–S60.
6.
MercadanteS, ValleA, PorzioG, et al.: How do cancer patients receiving palliative care at home die? A descriptive study. J Pain Symptom Manage, 2011; 42:702–709.
